| |
|
Production and use of blood products in the Regional Trutnov Hospital.
Rosová, Valérie ; Červená, Gabriela (advisor) ; Honegrová, Barbora (referee)
Title of Diploma Thesis: Production and use of transfusion products in the District Hospital Trutnov. Aim of the work: The aim was to evaluate the production of transfusion products (TP) in the period 2014-2019 at the Transfusion and Hematology Department (THO) in the District Hospital Trutnov and their use for hemotherapy by individual medical disciplines. Futhermore, to compare the production of TP within the Czech Republic together with selected European countries. The incidence of post-transfusion reactions and other adverse events during the reporting period is also included. Material and methods: The methodological part describes the standard procedures of pre- transfusion examination using the column agglutination method from the company Grifols, S.A., laboratory examination of donors and transfusion products manufactured at the Transfusion Department Trutnov. Conclusion: Despite all the recommendations and efforts to reduce the use of transfusion products, this condition has not been proven both in our department, within the Czech Republic and in Europe. This work recommends deleucotization of transfusion products for the national and European part, unification of procedures for transfusion in a given disease, mandatory introduction of NAT testing to minimize the risk of transmission...
|
|
Whole Blood - New Blood Component Containing Platelets
Nováková, Kateřina ; Červená, Gabriela (advisor) ; Honegrová, Barbora (referee)
Charles University Faculty of Pharmacy in Hradec Králové Department of Biological and Medical Sciences Candidate: Bc. Kateřina Nováková Supervisor: RNDr. Gabriela Červená, Ph.D. plk. MUDr. Miloš Bohoněk, Ph.D. Title of diploma thesis: Whole blood - New Blood Component Containing Platelets Background: The aim of this thesis was to evaluate in vitro quality parameters and haemostatic function of leucodepleted WB and their comparison with non-leucodepleted WB. The same way the quality parameters (RBC, PLT, HB and hemolysis) of erythrocyte blood component were measured and compared in day D14, D21, D35 and D42. Methods: WB collected from 30 healthy group A donors was divided into two groups - leucodepleted (LWB), using in-line platelet-sparing filters and collected to a blood bag system IMUFLEX® WB-SP (Terumo BCT, USA) and non-leucodepleted WB (NLWB), colletected to a blood bag system CompoFlex® Single System (Fresenius Kabi, Germany). Both groups were stored at 42řC for 14 days and following parameters were measured in days D0, D1, D3, D5, D10 and D14: WBC, RBC, PLT, HB, hemolysis, pH, TEG, FVIII, TT, PT, aPTT, aggregometry, concentration of PF4 and sCD40L (ELISA). Moreover, in days D0, D7 and D14 was measured the level of expression of platelet activation marker CD62P (P-selectin), CD42b, CD61 by...
|
|
Quality control of blood products
NOVÁČKOVÁ, Barbora
The main theme of this bachelor thesis is a quality control of blood products which are prepared in the Transfusion Centre in the České Budějovice Hospital. In my thesis, I focus on the rudimentary blood products manufactured from whole blood. These include resuspended erythrocytes without a buffy coat (EBR), plasma (P), mixed thrombocytes without leukocytes from a buffy coat in a spare solution (TBSDR) and mixed thrombocytes without leukocytes (TBSD). The aim of this work is a statistical analysis of quality of the aforementioned blood products used in the past 5 years. Moreover, I have devised my own quality control of the newest blood products TBSDR. The theoretical part addresses blood donors´ control, methods of blood collection, blood processing and procedures which may significantly influence the quality of blood products. I also describe the examined blood products and the quality control process. In the practical part, I deal with the procedure of examining the particular parameters of blood products´ quality control and their assessment. After the preparation of blood products, sampling is done as well as the control of both efficient and undesirable components (erythrocytes, leukocytes, thrombocytes, hemoglobin, hematocrit). Assessment of stability and sterility of blood products (hemolysis, pH, coagulation factors) is done at the end of their expiration. I will focus more carefully on the TBSDR blood product quality control which starts one month after the blood product is implemented into a production process and which lasts six months. Statistical control of the process is applied during the quality control. In the past 5 years, the quality of blood products has been satisfactory. The newly implemented blood product TBSDR is more high-quality than the previous TBDS. TBSDR provides not only patients but also transfusion centers with many advantages.
|
| |